首页 | 本学科首页   官方微博 | 高级检索  
检索        


Bevacizumab as adjuvant therapy in the management of pterygium: a systematic review and Meta-analysis
Authors:Jian Liu  Jie-Hui Xu  Wen Xu  Guan-Lu Liang  Ji-Xian Lou  Yi Wang  Ji-Quan Wen and Yong-Bao Cao
Institution:Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Eye Center, the Second Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou 310009, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China,Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China and Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China
Abstract:AIM: To evaluate the clinical effect of bevacizumab in pterygium treatment. METHODS: A systematic review and quantitative Meta-analysis was performed. PubMed, EMBASE, Web of Science and Cochrane database were searched for eligible literatures published in English until June 2016. The endpoint was recurrence rate and pooled risk ratio (RR) was calculated. RESULTS: Nine eligible studies were included and Meta-analysis results showed no significantly difference in patients treated with bevacizumab in short term follow-up 3mo: RR=0.70 (0.34, 1.45); 6mo: RR=0.55 (0.23, 1.32)] compared with control groups. No significant effects were observed in favor of bevacizumab in subgroup analyses: patients with subconjunctival injection of bevacizumab 3mo: RR=0.95 (0.70, 1.29); 6mo: RR=0.83 (0.55, 1.28)], primary pterygium 3mo: RR=0.59 (0.23, 1.54; 6mo: RR=0.59 (0.23, 1.53)], simple pterygium excision 3mo: 0.32 (0.05, 2.04), P=0.23; 6mo: 0.27 (0.05, 1.53)] and excision with conjunctival autograft 3mo: 1.51 (0.25, 9.15); 6mo: 1.11 (0.06, 21.69)]. CONCLUSION: In this Meta-analysis, we did not found the significant effect of bevacizumab in pterygium treatment, at least in short term follow-up (3mo and 6mo).
Keywords:pterygium  bevacizumab therapy  recurrence  Meta-analysis
点击此处可从《国际眼科杂志(英文版)》浏览原始摘要信息
点击此处可从《国际眼科杂志(英文版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号